{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:40:08Z","timestamp":1792644008858,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022720","name":"Fondazione Regionale per la Ricerca Biomedica","doi-asserted-by":"publisher","award":["D2020-151"],"award-info":[{"award-number":["D2020-151"]}],"id":[{"id":"10.13039\/501100022720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022720","name":"Fondazione Regionale per la Ricerca Biomedica","doi-asserted-by":"publisher","award":["GA 779282"],"award-info":[{"award-number":["GA 779282"]}],"id":[{"id":"10.13039\/501100022720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero Italiano della Salute","doi-asserted-by":"crossref","award":["JTC-2022"],"award-info":[{"award-number":["JTC-2022"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Among the broad spectrum of membranoproliferative glomerulonephritis (MPGN), immunofluorescence distinguishes C3 glomerulopathy (C3G), with predominant C3 deposits, and immunoglobulin-associated MPGN (Ig-MPGN), with combined C3 and Ig. However, there are several intersections between C3G and Ig-MPGN. Primary C3G and Ig-MPGN share the same prevalence of low serum C3 levels and of abnormalities of the alternative pathway of complement, and patients who present a bioptic pattern of Ig-MPGN at onset may show a C3G pattern in a subsequent biopsy. There is no specific therapy for primary C3G and Ig-MPGN and prognosis is unfavourable. The only recommended indications are inhibitors of the renin\u2013angiotensin system, lipid-lowering agents and other renoprotective agents. The other drugs used currently, such as corticosteroids and mycophenolate mofetil, are often ineffective. The anti-C5 monoclonal antibody eculizumab has been tested in several patients, with mixed results. One reason for the uncertainty is the extremely variable clinical course, most likely reflecting a heterogeneous pathogenesis. An unsupervised clustering analysis that included histologic, biochemical, genetic and clinical data available at onset in patients with primary C3G and Ig-MPGN identified four clusters characterized by specific pathogenic mechanisms. This approach may facilitate accurate diagnosis and development of targeted therapies. Several trials are ongoing with drugs targeting different molecules of the complement cascade, however it is important to consider which component of the cascade may be the most appropriate for each patient. We review the current standards of treatment and discuss novel developments in the pathophysiology, diagnosis, outcome prediction and management of C3G and Ig-MPGN.<\/jats:p>","DOI":"10.1093\/ndt\/gfad182","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T22:43:16Z","timestamp":1692657796000},"page":"202-214","source":"Crossref","is-referenced-by-count":39,"title":["C3G and Ig-MPGN\u2014treatment standard"],"prefix":"10.1093","volume":"39","author":[{"given":"Marina","family":"Noris","sequence":"first","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo e Cele Dacc\u00f2 Ranica , Bergamo , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo e Cele Dacc\u00f2 Ranica , Bergamo , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"2024013104480308600_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfab281","article-title":"Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment","volume":"38","author":"Noris","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104480308600_bib2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.kint.2020.05.053","article-title":"Practical management of C3 glomerulopathy and ig-mediated MPGN: facts and uncertainties","volume":"98","author":"Fakhouri","year":"2020","journal-title":"Kidney Int"},{"key":"2024013104480308600_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"2024013104480308600_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024013104480308600_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/Immune complex-mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2024013104480308600_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/imr.13167","article-title":"Kidney diseases","volume":"313","author":"Daina","year":"2023","journal-title":"Immunol Rev"},{"key":"2024013104480308600_bib7","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3389\/fimmu.2018.02329","article-title":"Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN","volume":"9","author":"Donadelli","year":"2018","journal-title":"Front Immunol"},{"key":"2024013104480308600_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1681\/ASN.2017111183","article-title":"Clusters not classifications: making sense of complement-mediated kidney injury","volume":"29","author":"Cook","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2024013104480308600_bib9","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(22)00461-5","article-title":"Acute glomerulonephritis","volume":"399","author":"Sethi","year":"2022","journal-title":"Lancet"},{"key":"2024013104480308600_bib10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ckj\/sfz178","article-title":"Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study","volume":"14","author":"P\u00e9rez de Jos\u00e9","year":"2021","journal-title":"Clin Kidney J"},{"key":"2024013104480308600_bib11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3748\/wjg.v18.i8.821","article-title":"Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis","volume":"18","author":"Zheng","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2024013104480308600_bib12","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/ndt\/gfab302","article-title":"C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104480308600_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.nefro.2017.03.012","article-title":"Monoclonal gammopathies of renal significance","volume":"37","author":"Caravaca-Font\u00e1n","year":"2017","journal-title":"Nefrologia"},{"key":"2024013104480308600_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2024013104480308600_bib15","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1681\/ASN.2012040390","article-title":"Mechanisms and treatment of CKD","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2024013104480308600_bib16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5301\/JN.2011.7763","article-title":"The Remission Clinic approach to halt the progression of kidney disease","volume":"24","author":"Remission Clinic Task Force, Clinical Research Center \u201cAldo e Cele Dacc\u00f2\u201d.","year":"2011","journal-title":"J Nephrol"},{"key":"2024013104480308600_bib17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO Clinical Practice Guideline for Lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"2024013104480308600_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.coph.2017.03.006","article-title":"ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease","volume":"33","author":"Perico","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"2024013104480308600_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/biomedicines11020279","article-title":"SGLT2 Inhibitors in diabetic and non-diabetic chronic kidney disease","volume":"11","author":"Podest\u00e0","year":"2023","journal-title":"Biomedicines"},{"key":"2024013104480308600_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome","volume":"38","author":"Trautmann","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"2024013104480308600_bib21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00467-021-05088-7","article-title":"A clinical approach to children with C3 glomerulopathy","volume":"37","author":"Vivarelli","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"2024013104480308600_bib22","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024013104480308600_bib23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"key":"2024013104480308600_bib24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00467-009-1322-7","article-title":"Membranoproliferative glomerulonephritis","volume":"25","author":"Alchi","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"2024013104480308600_bib25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2215\/CJN.16801221","article-title":"Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis","volume":"17","author":"Lomax-Browne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024013104480308600_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00467-020-04736-8","article-title":"Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis","volume":"36","author":"Khandelwal","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2024013104480308600_bib27","doi-asserted-by":"crossref","first-page":"2180508","DOI":"10.1155\/2017\/2180508","article-title":"Rituximab for treatment of membranoproliferative glomerulonephritis and C3 glomerulopathies","volume":"2017","author":"Rudnicki","year":"2017","journal-title":"Biomed Res Int"},{"key":"2024013104480308600_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"2024013104480308600_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-0034-1375299","article-title":"Treatment of C3 glomerulopathy with complement blockers","volume":"40","author":"Vivarelli","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"2024013104480308600_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12882-023-03058-9","article-title":"Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study","volume":"24","author":"Welte","year":"2023","journal-title":"BMC Nephrol"},{"key":"2024013104480308600_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ajkd.2018.12.046","article-title":"C5 Convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial","volume":"74","author":"Ruggenenti","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2024013104480308600_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2024013104480308600_bib33","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ekir.2022.01.124","article-title":"POS-112 Effect of avacopan, a selective C5a receptor inhibitor, on complement 3 glomerulopathy histologic index of disease chronicity","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024013104480308600_bib34","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ekir.2020.10.037","article-title":"Efficacy of eculizumab in coexisting complement C3 glomerulopathy and atypical hemolytic uremic syndrome","volume":"6","author":"Busutti","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024013104480308600_bib35","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s00467-023-05927-9","article-title":"Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis","volume":"38","author":"Riedl Khursigara","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"2024013104480308600_bib36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ndt\/gfac148","article-title":"Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation","volume":"38","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104480308600_bib37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/MNH.0000000000000358","article-title":"Recurrent glomerular disease after kidney transplantation","volume":"26","author":"Blosser","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2024013104480308600_bib38","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2014.02.006","article-title":"Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications","volume":"133","author":"Howrylak","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2024013104480308600_bib39","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/mds.23116","article-title":"The identification of Parkinson's disease subtypes using cluster analysis: a systematic review","volume":"25","author":"van Rooden","year":"2010","journal-title":"Mov Disord"},{"key":"2024013104480308600_bib40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ckj\/sfz073","article-title":"Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis","volume":"13","author":"Garam","year":"2020","journal-title":"Clin Kidney J"},{"key":"2024013104480308600_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfad079","article-title":"Complement inhibitors for kidney disease","author":"Wooden","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104480308600_bib42","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.2174\/0929867326666191001130342","article-title":"Discovery and development of the oral complement factor D inhibitor danicopan (ACH-4471)","volume":"27","author":"Wiles","year":"2020","journal-title":"Curr Med Chem"},{"key":"2024013104480308600_bib43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1159\/000527166","article-title":"Baseline clinical characteristics and complement biomarkers of patients with C3 glomerulopathy enrolled in two phase 2 studies investigating the factor D inhibitor danicopan","volume":"53","author":"Podos","year":"2022","journal-title":"Am J Nephrol"},{"key":"2024013104480308600_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"key":"2024013104480308600_bib45","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.4049\/jimmunol.1701668","article-title":"Contribution of adipose-derived factor D\/Adipsin to complement alternative pathway activation: lessons from lipodystrophy","volume":"200","author":"Wu","year":"2018","journal-title":"J Immunol"},{"key":"2024013104480308600_bib46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ki.1988.214","article-title":"Metabolism of complement factor D in renal failure","volume":"34","author":"Pascual","year":"1988","journal-title":"Kidney Int"},{"key":"2024013104480308600_bib47","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.1016\/j.ekir.2022.04.067","article-title":"POS-045 evaluating BCX9930, an oral factor D inhibitor for treatment of complement-mediated kidney disease: a proof-of-concept study (RENEW)","volume":"7","author":"Nester","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024013104480308600_bib48","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024013104480308600_bib49","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/j.ekir.2023.02.610","article-title":"WCN23-0403 An open-label, non-randomized extension study to evaluate long-term efficacy, safety, and tolerability of Lnp023 in subjects with C3 glomerulopathy: interim analysis of phase 2 study","volume":"8","author":"Nester","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2024013104480308600_bib50","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024013104480308600_bib51","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/j.ekir.2023.02.619","article-title":"WCN23-0584 A multicenter, randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy and safety of Iptacopan in idiopathic immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)","volume":"8","author":"Veldandi","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2024013104480308600_bib52","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","author":"Dixon","year":"2023","journal-title":"KI Reports"},{"key":"2024013104480308600_bib53","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.ekir.2022.04.069","article-title":"POS-047 Phase 2 study to evaluate efficacy and safety of pegcetacoplan in the treatment of patients with posttransplant recurrence of C3G or IC MPGN","volume":"7","author":"Palakow","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024013104480308600_bib54","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/j.ekir.2022.04.070","article-title":"POS-048 Phase 3, randomized, multicenter study to evaluate the efficacy and safety of pegcetacoplan in treatment of C3g or IC-MPGN","volume":"7","author":"Remuzzi","year":"2022","journal-title":"Kidney Int Rep"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad182\/53980080\/gfad182.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/2\/202\/56437498\/gfad182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/2\/202\/56437498\/gfad182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:16:22Z","timestamp":1706660182000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/2\/202\/7246920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,8,21]]},"published-print":{"date-parts":[[2024,1,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad182","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,8,21]]}}}